NCT04601584招募中1 期
Dose-escalation Sequention Cohort Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNR-084 in Patients With Refractory or Relapse Acute Lymphoblastic B-cell Precursor Leukemia.
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- AO GENERIUM
- 入组人数
- 36
- 试验地点
- 6
- 主要终点
- GNR-084 safety and tolerability.
研究概览
简要总结
It is an open-label dose-escalating study in sequential cohorts to assess safety and pharmacokinetics of GNR-084.
详细描述
Acute lymphoblastic leukemias (ALL) are a heterogeneous group of malignant clonal diseases of the blood system originating from precursor cells of hematopoiesis, predominantly of lymphoid differentiation.
More than 7,200 new cases of ALL are diagnosed annually in the European Union (EU), with approximately 40% (approximately 3,000 cases) occurring in adults The main reason for the failure of treatment of acute B-cell lymphoblastic leukemias (B-ALL) is the primary refractoriness to chemical exposure and relapses of the disease, which actually occur in 40-50% of adult patients with ALL. The prognosis in these cases is regarded as extremely unfavorable. Escalation of the chemotherapeutic approach is associated with the development of severe toxic infectious and hemorrhagic complications.
The active substance of the preparation GNR-084 is a bispecific antibody to CD19 / CD3 in the BiMS format (bispecific IgG-like molecules).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily signed informed consent form to participate in the study;
- •Men and women between aged 18 to 45 inclusive;
- •Patients with incurable morphologically / immunophenotypically confirmed refractory/ relapse of B-cell precursors CD19-positive acute lymphoblastic leukemia from (Ph "-" or Ph "+").
- •Two or more previous lines of anti-leucosis therapy.
- •5-50% of bone marrow blast cells at screening;
- •Functional status on the scale of the Eastern Cooperative Oncology Group (ECOG) 0-2 points at the screening;
- •Life expectancy ≥ 60 days;
排除标准
- •Hematopoietic stem cells transplantation within 12 weeks prior to study inclusion;
- •Active and widespread chronic graft versus host (GVHD) reaction (grade II-IV), including taking immunosuppressants for the prevention and treatment of GVHD within 2 weeks prior the GNR-084 infusion;
- •Investigator and / or sponsor has doubts that patient will complete the study due to rapid disease progression;
- •Chemotherapeutic agent using within 14 days prior the first GNR-084 infusion;
- •Exceptions:
- •Emergency leukapheresis;
- •Emergency hydroxyurea using due to hyperleukocytosis for ≤ 7 days;
- •Other supportive care, including antibiotics, at Investigator's discretion
- •Biochemical blood test:
- •The level of total bilirubin> 1.5 upper limit of norm;
- •Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT)> 3 upper limit of norm;
- •Glomerular filtration rate (GFR) level ≤30 (СKD-EPI)
- •Medical history of blinatumomab and other bispecific antibodies using;
- •Persistent toxicity event of 3rd and 4th severity degrees (CTCAE ver 5.0) due to previous treatment;
- •HIV-positive status and / or detection of any hepatitis B and / or hepatitis C blood markers;
- •Severe cardiovascular diseases: uncontrolled arterial hypertension, New York Heart Association (NYHA) functional class III or IV chronic heart failure, unstable angina pectoris, stroke, myocardial infarction, transient ischemic attack, coronary artery bypass grafting and coronary revascularization within last 12 months, or signs of pericardial effusion;
- •Individual sensitivity to:
- •GNR-084 components / excipients;
- •human or humanized investigational drug antibodies;
- •Major surgical interventions, accompanied by hospitalization and anesthesia application within 30 days before the patient is included in the study (biopsy is not a significant surgical intervention);
- •Any other malignant neoplasm presence at the present time or within 5 years prior to inclusion in the study;
- •Known suspected Central Nervous System (CNS) lesion by any genesis now or in medical history, including, but not limited to: neuroleukemia, epilepsy, ischemic or hemorrhagic stroke, severe traumatic brain injury, dementia, Parkinson's disease, organic brain damage, cerebellar disorders, psychosis;
- •Extramedullary lesion of any localization;
- •Other clinical trials participation within 30 days before screening;
- •Mental, physical and other reasons hindering patient to adequately assess their behavior and correctly comply with the conditions of the research protocol;
- •Pregnancy and / or lactation;
- •Male and female patients refusal to use adequate methods of contraception throughout the study;
- •Drug addiction;
- •Alcohol addiction.
研究组 & 干预措施
GNR-084, dose level 1
Experimental
Anti-CD19/CD3 antibody
干预措施: Cohort 1, GNR-084 (Biological)
GNR-084, dose level 2
Experimental
Anti-CD19/CD3 antibody
干预措施: Cohort 2, GNR-084 (Biological)
GNR-084, dose level 3
Experimental
Anti-CD19/CD3 antibody
干预措施: Cohort 3, GNR-084 (Biological)
GNR-084, dose level 4
Experimental
Anti-CD19/CD3 antibody
干预措施: Cohort 4, GNR-084 (Biological)
GNR-084, dose level 5
Experimental
Anti-CD19/CD3 antibody
干预措施: Cohort 5, GNR-084 (Biological)
GNR-084, dose level 6
Experimental
Anti-CD19/CD3 antibody
干预措施: Cohort 6, GNR-084 (Biological)
结局指标
主要结局
GNR-084 safety and tolerability.
时间窗: Week 10
The GNR-084 safety and tolerability will be assessed based on an analysis of the frequency of adverse events (AEs) over the period of treatment and observation of patients
次要结局
- GNR-084 Peak Plasma Concentration (Cmax)(First infusion: 5 minutes before administration, immediately after infusion, 30 minutes, 1, 3, 6, 12, 18, 24, 48, 72, 96 hours after infusion.)
- GNR-084 area under the plasma concentration versus time curve (AUC)(First infusion: 5 minutes before administration, immediately after infusion, 30 minutes, 1, 3, 6, 12, 18, 24, 48, 72, 96 hours after infusion.)
- GNR-084 elimination rate constant (Kel)(First infusion: 5 minutes before administration, immediately after infusion, 30 minutes, 1, 3, 6, 12, 18, 24, 48, 72, 96 hours after infusion.)
- GNR-084 overall clearance (Cl)(First infusion: 5 minutes before administration, immediately after infusion, 30 minutes, 1, 3, 6, 12, 18, 24, 48, 72, 96 hours after infusion.)
- Peripheral B-cells/T-cells ratio(First infusion: 5 minutes before administration, 30 minutes, 1, 24, 48, 96 and 144 hours after infusion. Other infusions: 5 minutes before administration and 1 hour after infusion)
- Immunogenicity(Week 33)
- GNR-084 mean retention time (MRT)(First infusion: 5 minutes before administration, immediately after infusion, 30 minutes, 1, 3, 6, 12, 18, 24, 48, 72, 96 hours after infusion.)
- CD45+ peripheral cell count(First infusion: 5 minutes before administration, 30 minutes, 1, 24, 48, 96 and 144 hours after infusion. Other infusions: 5 minutes before administration and 1 hour after infusion)
- Peripheral T-lymphocytes count (CD3, CD4, CD8)(First infusion: 5 minutes before administration, 30 minutes, 1, 24, 48, 96 and 144 hours after infusion. Other infusions: 5 minutes before administration and 1 hour after infusion)
- Peripheral T-memory cells (CD45RA+, CD28+, CCR7+) count(First infusion: 5 minutes before administration, 30 minutes, 1, 24, 48, 96 and 144 hours after infusion. Other infusions: 5 minutes before administration and 1 hour after infusion)
- Cytokine dynamics(First infusion: 5 minutes before administration, 30 minutes, 1, 24, 48, 96 and 144 hours after infusion. Other infusions: 5 minutes before administration and 1 hour after infusion)
- The frequency of specific toxicity events(Week 104)
- GNR-84 half-life (T1/2)(First infusion: 5 minutes before administration, immediately after infusion, 30 minutes, 1, 3, 6, 12, 18, 24, 48, 72, 96 hours after infusion.)
- GNR-084 kinetic volume of distribution (Vz)(First infusion: 5 minutes before administration, immediately after infusion, 30 minutes, 1, 3, 6, 12, 18, 24, 48, 72, 96 hours after infusion.)
- Peripheral blood B-lymphocyte depletion (CD19, CD20).(First infusion: 5 minutes before administration, 30 minutes, 1, 24, 48, 96 and 144 hours after infusion. Other infusions: 5 minutes before administration and 1 hour after infusion)
- Objective response rate (ORR)(After 2 and 5 GNR-084 cycles (each cycle is 28 days))
- Complete clinical and hematological remission rate (CR)(After 2 and 5 GNR-084 cycles (each cycle is 28 days))
- Frequency of complete remission with incomplete restoration of blood cellularity (CRi)(After 2 and 5 GNR-084 cycles (each cycle is 28 days))
- Event-free survival (EFS)(Week 104)
- Overall survival (OS)(Week 104)
- Duration of an objective response (DoR)(Week 104)
- Relapse-free survival (RFS)(Week 104)
- Minimal residual disease (MRD) (-) rate in CR-patient(After 5 GNR-084 cycles (each cycle is 28 days))
研究者
研究点 (6)
Loading locations...
相似试验
已完成
1 期
Safety and Pharmacokinetics of GNR-038 in Healthy VolunteersHereditary AngioedemaNCT04557319AO GENERIUM36
已完成
1 期
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung CancerBreast Cancer, Non-small Lung CancerNCT01862081Genentech, Inc.80
已完成
1 期
COM902 (A TIGIT Inhibitor) in Subjects With Advanced MalignanciesAdvanced CancerPlasma Cell NeoplasmHNSCCMicrosatellite Stable Colorectal CarcinomaMSS-CRCOvarian CancerLung CancerColon CancerMultiple MyelomaNCT04354246Compugen Ltd94
已完成
1 期
A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast CancerHER2-negative Metastatic Breast CancerNCT05261269Dantari, Inc.30
已完成
1 期
A Study of DT2216 in Relapsed/Refractory MalignanciesSolid TumorHematologic MalignancyNCT04886622Dialectic Therapeutics, Inc20